More evidence for benefits of GLP-1 agonists and SGLT2 inhibitors that go well beyond just treating diabetes.
#dementiaHD #alzheimersHD #sglt2HD #glucoseHD #diabetesHD #sglt2dementiaHD
JAMA Neurology report shared by Louis: in people with type 2 diabetes, both GLP-1 receptor agonists and SGLT2 inhibitors were associated with decreased risk of Alzheimer disease and related dementias compared with other glucose-lowering drugs. Louis sees this as evidence for benefits beyond diabetes treatment.
More evidence for benefits of GLP-1 agonists and SGLT2 inhibitors that go well beyond just treating diabetes.
#dementiaHD #alzheimersHD #sglt2HD #glucoseHD #diabetesHD #sglt2dementiaHD
Most viewed in the last 7 days from JAMA Neurology: In people with type 2 diabetes, both GLP-1RAs and SGLT2is were associated with decreased risk of Alzheimer disease and related dementias vs other glucose-lowering drugs.
Paper · JAMA NeurologyJAMA Neurology articleja.ma